Nutraceutix receives Chinese patent for probiotic and nutraceutical delivery technology

The Chinese Patent Office has issued Nutraceutix, Inc. patent No. 02823678.5 for BIO-tract. It is the fourth international patent, from many patents pending, that the technology has been awarded recently based on BIO-tract's ability to protect sensitive ingredients such as probiotic organisms from stomach acid on their way to optimal release sites in the intestinal tract.

Steve Moger, President and CEO of Nutraceutix, comments: "Years ago, we recognized the need for an effective probiotic and nutraceutical delivery technology -- one that draws upon proven pharmaceutical principles, yet is economically feasible in the nutritional supplement marketplace. Our research and development investments in BIO-tract continue to be validated by yet another key patent." Randy Schoenfeldt, Senior Vice President for Nutraceutix, adds: "This latest patent is particularly significant due to the enormous size and potential of the market in China."

BIO-tract products overcome the three major barriers to effective probiotic supplementation:

  • Survival of beneficial, but fragile organisms through the manufacturing process
  • Survival on the store shelf over extended timeframes, even at room temperature
  • Survival past harsh stomach acids that denature unprotected probiotic organisms

Nutraceutix, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Reframing the understanding of stress can make a big difference to students' wellbeing, success